Immunotherapy: opportunities, risks and future perspectives

被引:8
作者
Hildebrandt, Martin [1 ]
Peggs, Karl [2 ]
Uharek, Lutz [3 ]
Bollard, Catherine M. [4 ]
Heslop, Helen E. [5 ]
机构
[1] Tech Univ Munich, TUMCells Interdisciplinary Ctr Cellular Therapies, Fac Med, D-81675 Munich, Bavaria, Germany
[2] Univ Coll London Hosp, Res Dept Hematol, London, England
[3] Charite, Dept Hematol & Oncol, D-13353 Berlin, Germany
[4] Childrens Natl Hlth Syst, Ctr Canc & Immunol Res, Washington, DC USA
[5] Baylor Coll Med & Pediat, Houston, TX USA
关键词
clinical trials; gene therapy; immunotherapy; safety; T cell receptor; treatment efficacy; EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; STEM-CELL TRANSPLANTATION; ADOPTIVE TRANSFER; GENETIC-MODIFICATION; COMPLETE RESPONSES; PHASE-I; THERAPY; EBV; CMV;
D O I
10.1016/j.jcyt.2014.02.001
中图分类号
Q813 [细胞工程];
学科分类号
摘要
This review is intended to reflect upon the current status and perspectives of cell-based immunotherapy at a time when the promise of extensive pre-clinical research has been translated into encouraging clinical responses. However, some of these have also been complicated by significant adverse reactions. As the field moves towards definitive late stage trials, with a growing interest from pharmaceutical companies, we realize that novel cell therapy strategies pose questions that are familiar to traditional drug development, along with new considerations due to the potential of T cells to persist long term and to expand after adoptive transfer. These questions address the safety of the product, the efficacy, the mode of action, and the anticipation of risks. From different perspectives, we intend to address exciting opportunities and safety concerns in current concepts of cellular immunotherapy.
引用
收藏
页码:S120 / S129
页数:10
相关论文
共 68 条
  • [1] [Anonymous], ADV HEMATOL
  • [2] [Anonymous], 2006, EXP SCI GROUP PHAS C
  • [3] Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation
    Blyth, Emily
    Clancy, Leighton
    Simms, Renee
    Ma, Chun K. K.
    Burgess, Jane
    Deo, Shivashni
    Byth, Karen
    Dubosq, Ming-Celine
    Shaw, Peter J.
    Micklethwaite, Kenneth P.
    Gottlieb, David J.
    [J]. BLOOD, 2013, 121 (18) : 3745 - 3758
  • [4] Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
    Bollard, Catherine M.
    Gottschalk, Stephen
    Leen, Ann M.
    Weiss, Heidi
    Straathof, Karin C.
    Carrum, George
    Khalil, Mariam
    Wu, Meng-fen
    Huls, M. Helen
    Chang, Chung-Che
    Gresik, M. Victoria
    Gee, Adrian P.
    Brenner, Malcolm K.
    Rooney, Cliona M.
    Heslop, Helen E.
    [J]. BLOOD, 2007, 110 (08) : 2838 - 2845
  • [5] T-cell therapy in the treatment of post-transplant lymphoproliferative disease
    Bollard, Catherine M.
    Rooney, Cliona M.
    Heslop, Helen E.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (09) : 510 - 519
  • [6] Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
    Bollard, CM
    Aguilar, L
    Straathof, KC
    Gahn, B
    Huls, MH
    Rousseau, A
    Sixbey, J
    Gresik, MV
    Carrum, G
    Hudson, M
    Dilloo, D
    Gee, A
    Brenner, MK
    Rooney, CM
    Heslop, HE
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12) : 1623 - 1633
  • [7] Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity
    Bollard, CM
    Rössig, C
    Calonge, MJ
    Huls, MH
    Wagner, HJ
    Massague, J
    Brenner, MK
    Heslop, HE
    Rooney, CM
    [J]. BLOOD, 2002, 99 (09) : 3179 - 3187
  • [8] Bollard CM, 2013, J CLIN ONCOL
  • [9] CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
    Brentjens, Renier J.
    Davila, Marco L.
    Riviere, Isabelle
    Park, Jae
    Wang, Xiuyan
    Cowell, Lindsay G.
    Bartido, Shirley
    Stefanski, Jolanta
    Taylor, Clare
    Olszewska, Malgorzata
    Borquez-Ojeda, Oriana
    Qu, Jinrong
    Wasielewska, Teresa
    He, Qing
    Bernal, Yvette
    Rijo, Ivelise V.
    Hedvat, Cyrus
    Kobos, Rachel
    Curran, Kevin
    Steinherz, Peter
    Jurcic, Joseph
    Rosenblat, Todd
    Maslak, Peter
    Frattini, Mark
    Sadelain, Michel
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (177)
  • [10] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    Brentjens, Renier J.
    Riviere, Isabelle
    Park, Jae H.
    Davila, Marco L.
    Wang, Xiuyan
    Stefanski, Jolanta
    Taylor, Clare
    Yeh, Raymond
    Bartido, Shirley
    Borquez-Ojeda, Oriana
    Olszewska, Malgorzata
    Bernal, Yvette
    Pegram, Hollie
    Przybylowski, Mark
    Hollyman, Daniel
    Usachenko, Yelena
    Pirraglia, Domenick
    Hosey, James
    Santos, Elmer
    Halton, Elizabeth
    Maslak, Peter
    Scheinberg, David
    Jurcic, Joseph
    Heaney, Mark
    Heller, Glenn
    Frattini, Mark
    Sadelain, Michel
    [J]. BLOOD, 2011, 118 (18) : 4817 - 4828